GeoVax Labs Faces Nasdaq Delisting After Equity Shortfall
GOVX sits 24% above its 52-week low of $0.963.
Summary
GeoVax Labs received a Nasdaq delisting notice for failing the $2.5 million minimum stockholders' equity rule. The company has 45 days to propose a compliance plan, with a potential 180-day extension if accepted.
Key Events · Legal and Risk Events · GOVX
-
Nasdaq Delisting Notice Received
On July 7, 2026, GeoVax was notified it does not meet the $2.5 million minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.
-
Compliance Plan Deadline
The company has until August 21, 2026 (45 days) to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days to evidence compliance.
-
Severe Cash Crunch Context
The delisting notice follows a Q1 2026 report showing only $1.3 million in cash and a going concern warning, with funds projected to last only through June 2026.
-
Potential Delisting Consequences
If the plan is rejected or compliance is not achieved, Nasdaq will issue a delisting determination, though the company can request a hearing to stay the action.
Analysis · GOVX · Life Sciences
Nasdaq has notified GeoVax Labs that it falls short of the $2.5 million minimum stockholders' equity requirement. The company now has until August 21, 2026 to deliver a plan for regaining compliance. This development arrives during a severe cash crunch—the most recent quarterly filing disclosed just $1.3 million in cash and a going concern warning. The delisting notice intensifies the immediate pressure to raise capital; failure to do so could lead to removal from the Nasdaq Capital Market, which would severely impair liquidity and investor confidence.
At the time of this filing, GOVX was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.96 to $23.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.